VEGFA and glioblastoma: For example, introducing an SDF-1α (CXCL-12) inhibitor to anti-VEGF antibodies significantly reduced the level of TAMs and prolonged the survival time of glioblastoma-bearing rodents compared with the VEGF blockade alone [116].